XML 27 R7.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Revision of Prior Period, Reclassification, Adjustment
Treasury Stock
Retained Earnings (Accumulated Deficit)
Net Investment from J&J
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Jan. 01, 2023 [1]   0            
Beginning balance (in shares) at Jan. 01, 2023 [1]         0      
Beginning balance at Jan. 01, 2023 [1] $ 19,970 $ 0 $ 0   $ 0 $ 0 $ 25,425 $ (5,455)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income [1] 1,664         1,195 469  
Other comprehensive income (loss) [1] 155             155
Cash dividends on common stock ($0.83 per share) [1] (766)         (766)    
Net transfers to J&J [1] (308)           (308)  
Stock-based compensation [1] 188   153       35  
Distribution to J&J in connection with the Separation [1] (13,788)   (13,788)          
Issuance of common stock in connection with the Kenvue IPO (in shares) [1]   1,914,894,000            
Issuance of common stock in connection with the Kenvue IPO [1] 4,241 $ 19 4,222          
Issuance of common stock under the Kenvue 2023 Plan (in shares) [1]   513,000            
Issuance of common stock under the Kenvue 2023 Plan, net [1] 8   8          
Purchase of treasury stock (in shares) [1]   350,000     (350,000)      
Purchase of treasury stock [1] (7)       $ (7)      
Reclassification of Net Investment from J&J [1] 0   25,712       (25,712)  
Separation-related adjustments [1] (146)     $ (160)     91 (77)
Ending balance (in shares) at Dec. 31, 2023 [1]   1,915,057,000            
Ending balance (in shares) at Dec. 31, 2023 [1]         350,000      
Ending balance at Dec. 31, 2023 [1] 11,211 $ 19 16,147   $ (7) 429 0 (5,377)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 1,030         1,030    
Other comprehensive income (loss) (769)             (769)
Cash dividends on common stock ($0.83 per share) (1,552)         (1,552)    
Stock-based compensation 254   254          
Issuance of common stock under the Kenvue 2023 Plan (in shares)   9,569,000            
Issuance of common stock under the Kenvue 2023 Plan, net 69   69          
Purchase of treasury stock (in shares)   10,858,000     (10,858,000)      
Purchase of treasury stock (235)       $ (235)      
Separation-related adjustments $ (340)     $ (340)        
Ending balance (in shares) at Dec. 29, 2024 1,913,768,000 1,913,768,000            
Ending balance (in shares) at Dec. 29, 2024 11,208,000       11,208,000      
Ending balance at Dec. 29, 2024 $ 9,668 $ 19 16,130   $ (242) (93) 0 (6,146)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 1,470         1,470    
Other comprehensive income (loss) 1,187             1,187
Cash dividends on common stock ($0.83 per share) (1,581)         (1,581)    
Stock-based compensation 136   136          
Issuance of common stock under the Kenvue 2023 Plan (in shares)   11,526,000            
Issuance of common stock under the Kenvue 2023 Plan, net $ 82   82          
Purchase of treasury stock (in shares) (9,179,000) 9,179,000     (9,179,000)      
Purchase of treasury stock $ (197)       $ (197)      
Ending balance (in shares) at Dec. 28, 2025 1,916,115,445 1,916,115,000            
Ending balance (in shares) at Dec. 28, 2025 20,387,000       20,387,000      
Ending balance at Dec. 28, 2025 $ 10,765 $ 19 $ 16,348   $ (439) $ (204) $ 0 $ (4,959)
[1] Prior to April 4, 2023, the Company operated as a segment of J&J and not as a separate entity. The Company’s financial statements prior to April 4, 2023 were prepared on a combined basis and were derived from J&J’s historical consolidated financial statements and accounting records as if the Company had been operated on a standalone basis. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Basis of Presentation,” for more information.